Search company, investor...
Search

Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
venrock.com

See what CB Insights has to offer

Investments

1093

Portfolio Exits

275

Funds

21

Partners & Customers

2

Service Providers

2

About Venrock

Venrock was founded in 1969 as the venture capital arm of the Rockefeller Family. The company primarily provides seed or first round funding and services for entrepreneurs with breakthrough ideas in technology, healthcare, media, and energy.

Venrock Headquarters Location

3340 Hillview Avenue

Palo Alto, California, 94304,

United States

650-561-9580

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Venrock

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Venrock in 7 Expert Collections, including HR Tech.

H

HR Tech

65 items

B

Banking

44 items

Based on CB Insights Research Brief: https://www.cbinsights.com/blog/industry-market-map-landscape/#retail banking

B

Beauty & Personal Care

58 items

Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.

U

Unicorns- Billion Dollar Startups

114 items

S

Synthetic Biology

382 items

T

The Edge Computing Landscape

113 items

Edge computing companies facilitate workload deployment in addition to providing data processing and storage at the farthest reaches of the network. These edge computing companies range from data centers at the edge to workload management tools designed to orchestrate edge deploy

Venrock Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Venrock Rank

Research containing Venrock

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Venrock in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Venrock News

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

Aug 23, 2022

Download August 23, 2022 07:00 AM Eastern Daylight Time WALTHAM, Mass.--( BUSINESS WIRE )--Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has transitioned in order to pursue new opportunities. “We are delighted to have Dr. Gallant join our team at Mythic,” said Brian Fiske, PhD, Co-founder and Chief Scientific Officer. “His extensive experience in oncology drug development, in particular antibody-drug conjugates, and proven track record building and leading global clinical development teams will strengthen our capability to pursue the clinical development of our lead program in lung cancer as well as our broader product pipeline.” As Chief Development Officer, Dr. Gallant is responsible for the strategy, direction, and execution of the company’s clinical development program. He will provide leadership and direction to Clinical Operations, Clinical Sciences, Data Management/Biometrics, and Drug Safety. Dr. Gallant joins Mythic from Daiichi Sankyo, where he was Senior Vice President Global Head of Oncology Clinical Development and led the development of the company’s global oncology portfolio. At Daiichi, he built and led the team that guided the clinical development, the global regulatory submission and worldwide approval of the antibody-drug conjugate Enhertu® for the treatment of patients with advanced breast cancer, gastric cancer and lung cancer (NSCLC). Dr. Gallant previously held leadership roles in clinical oncology at Bristol Myers Squibb, Human Genome Sciences and Biomarin, leading programs for Taxol® and Talzenna™. He received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Québec, Canada and is a Fellow of the Order of Pharmacists of Québec (FOPQ). “I am delighted to be joining Mythic’s leadership team at an exciting time for the company and the field of ADCs,” said Dr. Gallant. “It is an extraordinary opportunity to blend the experience I have gained in research and development of ADCs in oncology with a truly creative approach to dramatically improve their clinical performance in both efficacy and safety." “On behalf of the entire Board of Directors, I want to welcome Gilles to Mythic as well as extend our sincere appreciation to Alex for his dedication and contributions to Mythic since its founding in 2017,” said Bryan Roberts, Partner of Venrock and a member of Mythic’s Board of Directors. “Beginning with nothing other than a mission to improve patient care, over the last five years Mythic has built a strong foundation and world-class team. The company is well-positioned to develop a pipeline of safer and more effective ADCs, beginning with its lead program.” The Mythic Board of Directors has initiated a search for Dr. Nichols’ successor. In the interim, Brian Fiske, PhD, Co-founder, and Chief Scientific Officer and Sandra Poole, MASc, PEng, Chief Operating Officer, together with Dr. Gallant, have assumed responsibilities for the operational management of the Company. About Mythic Therapeutics Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic’s ADCs. The Company’s major investors include Venrock, Viking Global Investors, and First Round Capital. For more information, visit: www.mythictx.com Contacts

Venrock Investments

1,093 Investments

Venrock has made 1,093 investments. Their latest investment was in Nightfall AI as part of their Series B on August 8, 2022.

CBI Logo

Venrock Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/10/2022

Series B

Nightfall AI

$40M

No

1

7/20/2022

Seed VC - III

DGraph

$6M

Yes

2

6/8/2022

Seed VC - II

Meltano

$8.2M

Yes

1

4/29/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/12/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/10/2022

7/20/2022

6/8/2022

4/29/2022

4/12/2022

Round

Series B

Seed VC - III

Seed VC - II

Series B

Series C

Company

Nightfall AI

DGraph

Meltano

Subscribe to see more

Subscribe to see more

Amount

$40M

$6M

$8.2M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

Venrock Portfolio Exits

275 Portfolio Exits

Venrock has 275 portfolio exits. Their latest portfolio exit was Misty Robotics on January 17, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/17/2022

Acquired

$99M

3

1/10/2022

Acquired

$99M

4

12/23/2021

Acquired

$99M

1

12/21/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/1/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/17/2022

1/10/2022

12/23/2021

12/21/2021

11/1/2021

Exit

Acquired

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

4

1

10

10

Venrock Fund History

21 Fund Histories

Venrock has 21 funds, including Venrock Healthcare Capital Partners EG.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/21/2020

Venrock Healthcare Capital Partners EG

$446.75M

1

4/20/2018

Venrock Healthcare Capital Partners III

Late-Stage Venture Capital

Closed

$400M

3

2/8/2017

Venrock Associates VIII

Early-Stage Venture Capital

Closed

$413.6M

4

7/31/2014

Venrock Associates VII

Subscribe to see more

Subscribe to see more

$99M

10

7/9/2010

Venrock Associates VI

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/21/2020

4/20/2018

2/8/2017

7/31/2014

7/9/2010

Fund

Venrock Healthcare Capital Partners EG

Venrock Healthcare Capital Partners III

Venrock Associates VIII

Venrock Associates VII

Venrock Associates VI

Fund Type

Late-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$446.75M

$400M

$413.6M

$99M

$99M

Sources

1

3

4

10

10

Venrock Partners & Customers

2 Partners and customers

Venrock has 2 strategic partners and customers. Venrock recently partnered with CoinFund on April 4, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

4/8/2018

Partner

United States

2

4/18/2013

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/8/2018

4/18/2013

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

Subscribe to see more

Subscribe to see more

Sources

2

10

Venrock Service Providers

2 Service Providers

Venrock has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Venrock Team

22 Team Members

Venrock has 22 team members, including current Chief Financial Officer, Lisa D. Harris.

Name

Work History

Title

Status

Lisa D. Harris

DCM Ventures, Sierra Ventures, and KPMG

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Lisa D. Harris

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

DCM Ventures, Sierra Ventures, and KPMG

Title

Chief Financial Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.